EGFR and non-small cell lung carcinoma: Dacomitinib, another highly selective, irreversible second-generation (2G) EGFR-TKI, has been approved as a first-line treatment in patients with NSCLC carrying classical EGFR mutations as it significantly improved progression-free survival (PFS) as compared with gefitinib in the ARCHER 1050 study [11].